Serum CCL11 Levels in Benign Prostatic Hyperplasia and Prostate Cancer

Abstract

Purpose: CC-chemokine ligand 11 (CCL11; eotaxin-1), an eosinophil chemoattractant chemokine, has been proposed as a serum marker for prostate cancer (PCa) by two research groups. We investigated the usefulness of CCL11 in diagnosing prostatic diseases, such as benign prostatic hyperplasia (BPH) and PCa. Materials and Methods: CCL11 was measured in the sera of 139 men with BPH, 44 men with PCa, and 45 control men attending an outpatient health-screening clinic. A commercial enzyme-linked immunosorbent assay kit was used to measure CCL11. Results: CCL11 concentrations were significantly higher in men with BPH and PCa than in normal men (72.9±3.15 and 80.0±4.91 pg/ml vs. 57.6±8.24). In addition, a receiver operating characteristic (ROC) analysis of serum CCL11 levels showed that the areas under the ROC curves were 0.661 (p=0.001) and 0.654 (p=0.012) for BPH and PCa, respectively, compared with normal men. Conclusions: CCL11 may be helpful in diagnosing prostatic diseases, such as BPH and PCa.

Comparison of Seropositivity to Trichomonas vaginalis between Men with Prostatic Tumor and Normal Men

“…Sera were obtained from 139 patients with BPH, 44 with prostate cancer and 58 male healthy volunteers (mean age: 40.4±0.15) who visited Hanyang University International Hospital Health Promotion Center. Healthy volunteers had no history of prostatic disease [14]. Blood samples of 7 ml were collected, and plasma was stored at −70°C.…”

A two‐CpG‐based prognostic signature for oral squamous cell carcinoma overall survival

“…35,36 CCL11, CCL18, and MMP-7, in combination with CA125 can be used for the diagnosis of epithelial ovarian cancer. 37 Kim et al 38 indicated that CCL11 might be helpful in the diagnosis of prostate cancer. It was shown that the expression of CHRDL1 was associated with the clinical outcomes in patients with breast cancer.…”